Septerna, Inc. (SEPN) research
Septerna, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $37.71
- As of
Septerna, Inc. (SEPN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-25.
As of . Source: SEC EDGAR filings for SEPN. Method and limitations.
Share the SEPN intelligence card
See the full SEPN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SEPN on one page. Preview it with sample data, then open it live with a free account.
Preview the SEPN dossierActive signals for SEPN
- highCONSENSUS_BUY
3 tracked funds increased SEPN this 2026Q2, institutional consensus
- highinsider_cluster_sell
2 insiders at SEPN sold $39.1M this week
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 33.3%, EPS $-0.29 vs $-0.4345 estimate
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 59% of SEPN (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 85% of SEPN (2026Q2)
FREE, NO ACCOUNT
Every signal on SEPN, as it fires
You are seeing 5 of 14 signals recorded on SEPN since 2026-05-26.
The five above landed across 4 days. The other 9 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SEPN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 81734D104 · 2026Q2 | $7.4M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 81734D104 · 2026Q2 | $1.7M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 81734D104 · 2026Q2 | $1.6M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 81734D104 · 2026Q2 | $1.4M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 81734D104 · 2026Q2 | $213K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SEPN
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SEPN against its peers
SEPN's operating margin of -148.6% ranks in the 44th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | SEPN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 46.0M USD | 74.7M USD | 28 | 15 |
| Operating margin | -148.6% | -127.5% | 44 | 16 |
| Net margin | -106.4% | -139.8% | 53 | 17 |
| Return on equity | -12.8% | -44.1% | 83 | 19 |
Peers (23): CMPS, ZBIO, NVAX, VIR, MESO, XNCR, ZYME, LKFT, BHVN, RXRX, AGIO, SRPT, URGN, NBTX, PVLA, STOK, FBRX, ABSI, TSHA, VCEL, GHRS, RAPP, NTLA. Left out: BRVE (no annual filing), GENB (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (SEPN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SEPN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SEPNand get the insider, 13F, options, and confluence read in one view.